The current research lines of the Polymer Therapeutics laboratory can be summarized as follows:
1. Development of new biodegradable polymers with defined structure to be used as versatile carriers in targeted drug delivery systems of bioactive agents.
i. Design of polymeric carriers able to cross the blood brain barrier.
ii. Design of polymeric carriers to enhance cytosolic transport of oligonucleotides, peptides, and / or proteins.
iii. New branched polyglutamates as imaging agents (i.e. neuroimaging) and for the treatments and diagnosis of neurodegenerative processes.
iv. New polymeric micelles and hybrid systems ('Scaffold-Polymer conjugate') with applications in tissue repair and regeneration (mainly Alzheimer’s Disease and Spinal Cord Injury).
2. Polymer Therapeutics designed as personalized combination therapies for the treatment of cancer and tissue regeneration.
i. Personalized polymer-based combination conjugates for breast and prostate cancer treatments in advanced/metastatic phases. Development of cellular and in vivo models from patients to allow personalized nanomedicine implementation.
ii. Biomarkers identification for the application of nanomedicines in clinics (vascularisation, protease levels, endocytic regulator proteins, metabolism, etc.), depending on the studied pathology and the disease stage.
iii. Design of polymer conjugates for theranostic approaches (imaging + therapy) with application to neurodegenerative processes.
3. Development of exhaustive characterization techniques (physico-chemical and biophysics) for cellular trafficking quantification (endocytosis) and in vivo biodistribution/PK.
i. Solution conformation studies of polymer conjugates (SANS, Diffusion NMR), and its influence in the therapeutic effect.
ii. Study of the endocytic mechanisms. Polymeric nanoconjugates intracellular trafficking control. Development of fluorescence and NMR probes.
iii. In vivo Pharmacokinetic-pharmacodynamic (PK-PD) study of the nanoconjugates. Development of imaging, PET, MRI, and dual probes.